Nuvation Bio's stock price rises, with multiple analysts setting new target prices

Summary

Nuvation Bio (NYSE:NUVB) shares rose 7.2% to $3.23, with analysts setting new price targets: HC Wainwright at $10.00 and Wedbush at $6.00. The stock has an average rating of ‘Buy’ and a target price of $7.50. The company reported $4.83 million in revenue for the last quarter, meeting EPS estimates. Nuvation Bio focuses on developing oncology therapeutics, including its lead candidate NUV-868.Market Beat

Impact Analysis

So basically, Nuvation Bio’s stock is on the move, up 7.2% with analysts setting ambitious new price targets—HC Wainwright at $10 and Wedbush at $6, against a current price of $3.23. This suggests a strong belief in the company’s oncology pipeline, particularly its lead candidate NUV-868. The recent FDA approval and promising Phase 2 results for IBTROZI™ are likely fueling this optimism.Market Beat+ 2 The interesting part isn’t just the price targets, but the underlying confidence in Nuvation’s ability to execute and potentially achieve profitability without needing additional funding, given their $608 million cash balance.Reuters However, the stock’s high RSI indicates it might be overbought, suggesting caution in the short term.Benzinga I’d read this as a potential long-term play, but watch for volatility as the market digests these developments.